Huagai Capital is the famous VC, which was founded in 2012. The leading representative office of defined VC is situated in the Beijing. The venture was found in Asia in China.
Opposing the other organizations, this Huagai Capital works on 17 percentage points less the average amount of lead investments. The typical startup value when the investment from Huagai Capital is 500 millions - 1 billion dollars. The fund is constantly included in 2-6 investment rounds annually. Speaking about the real fund results, this VC is 56 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2019. The increased amount of exits for fund were in 2018. The usual things for fund are deals in the range of 10 - 50 millions dollars.
The fund has exact preference in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Health Care, Pharmaceutical. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Tiger Brokers, EdiGene, Songxiaocai. For fund there is a match between the location of its establishment and the land of its numerous investments - China.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Huagai Capital, startups are often financed by Sequoia Capital China, Qiming Venture Partners, Qualcomm Ventures. The meaningful sponsors for the fund in investment in the same round are ZhenFund, Tranquility Capital, Sequoia Capital China. In the next rounds fund is usually obtained by Lilly Asia Ventures, IDG Capital, Green Pine Capital Partners.
This organization was formed by Lu Binghui, Xu Xiaolin. Besides them, we counted 2 critical employees of this fund in our database.
Related Funds
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Baijun Biotech | 19 Sep 2024 | - | |||
Ai Sensing Technology | 16 May 2024 | Guangdong, Tianjin, China | |||
Micro Interventional | 18 Mar 2024 | Hangzhou, Zhejiang, China | |||
Cybernetics | 26 Feb 2024 | Haidian, Beijing, China | |||
Utarn Technology | 19 Feb 2024 | Shangcheng District, Zhejiang, China | |||
Bowang Pharmaceutical | $46M | 01 Nov 2023 | Jiading, Shanghai, China | ||
Leo Summit | 08 Sep 2023 | Changping, Beijing, China | |||
Leaf Biotech | $30M | 25 Jun 2023 | Hefei, Anhui, China | ||
Dingzhi Biotech | 21 Jun 2023 | Daxing, Beijing, China |
– PAQ Therapeutics is a biotechnology company advancing a new approach to restoring health and curing disease through autophagy.
– The company announced the closing of a $30m Series A round.
– Sherpa Healthcare Partners led the round with participation from Huagai Capital, MSA Capital, and MRL Ventures Fund as well as seed investors Nest.Bio Ventures and Matrix Partners China.
– The funding will be used to advance the company’s ATTEC platform and progress its pipeline programs.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Baijun Biotech | 19 Sep 2024 | - | |||
Ai Sensing Technology | 16 May 2024 | Guangdong, Tianjin, China | |||
Micro Interventional | 18 Mar 2024 | Hangzhou, Zhejiang, China | |||
Cybernetics | 26 Feb 2024 | Haidian, Beijing, China | |||
Utarn Technology | 19 Feb 2024 | Shangcheng District, Zhejiang, China | |||
Bowang Pharmaceutical | $46M | 01 Nov 2023 | Jiading, Shanghai, China | ||
Leo Summit | 08 Sep 2023 | Changping, Beijing, China | |||
Leaf Biotech | $30M | 25 Jun 2023 | Hefei, Anhui, China | ||
Dingzhi Biotech | 21 Jun 2023 | Daxing, Beijing, China |